Economy “As Mexicans we must be prepared for a new stage of our country’s development”. These were the inspiring words of newly elected Mexican President Peña Nieto, who has promised to transform Mexico into a competitive global power. As the world’s thirteenth largest economy, there is no question that Mexico…
Generics In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths, and talks about the opportunities in Asia for companies that have followed a similar path to TTY. To read the…
Clinical trials The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science behind Traditional Chinese Medicine. What is the vision behind Vita Genomics? Vita Genomics was founded in 2001. At the time,…
Department of Investment Services The General Director of the ‘Invest in Taiwan’ program discusses Taiwan’s competitiveness on a global and regional level, highlights the areas and industrial sectors where the country is looking to invest, and talks about the importance of further economic integration with its neighbours in order to realize its potential. Can…
investment In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and biotech companies over the last fifteen years, and goes in-depth into the company’s innovative pipeline, including UBI’s possible HIV cure.…
CEO story In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her own personal history that led her to the creation of the company. To read the first part of this interview,…
Inlicensing The General Manager of OBI Pharma, a biopharmaceutical company currently working on a breast cancer drug, offers perspectives on developing a successful biotech company in Taiwan, the overall drug development ecosystem in Taiwan, and the acquire-develop-transfer model of doing business. Throughout our interviews in Taiwan, several industry stakeholders have expressed…
Generics Janssen has historically had a very strong focus on emerging markets. In today’s world, where growth for the pharmaceutical industry overwhelmingly comes from emerging markets, where do we find the Nordics? What is the relevance of the Nordics for the country’s global footprint? Jansen has preserved the cluster model. We…
investment Cormac Callaghan, founder and managing director of Primecore, a portfolio and program management consultancy based in Dublin and Cambridge, Massachusetts, has managed large-scale change programs for the pharmaceutical industry for the better part of 30 years. He has seen his share of setbacks: between 2006 and 2008, Callaghan was the…
BCF Business Law Gino Martel explains the present environment for M&As, divestitures and out-licensing in the Canadian biotech sector, the different ways that biotech companies can commercialize their scientific successes in the current market climate, and strategies for keep scientific talent in Canada. How do mergers and acquisitions in the pharmaceutical industry in…
Biotech City The director of Biotech City in Laval, close to Montreal, discusses the advantages brought on by the cluster effect, and how this has played out at Biotech City, a government funded cluster of 80 companies and over 5,000 employees. Your background has a strong focus on business start-ups and development,…
CNS The head of Lundbeck in Canada talks about the stigma of mental illness that still exists in the country today, and how CNS companies like Lundbeck are working with stakeholders to help overcome this problem, so that sufferers of depression are treated as though they have a disease. Your…
See our Cookie Privacy Policy Here